Get 20% Free Customization In This Report

Buy this report from - $3456

Nifedipine Market by Product (Nifedipine Controlled Release Tablets and Nifedipine Extended Release Tablets), by Application (Primary Pulmonary Hypertension, Heart Failure, Ryanoidâ€™s Disease, Cephalagra, Bronchial Asthma and Premature Labor) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI_184003	Pages: NA	Jul 2018 \| 473 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Nifedipine is a drug that belongs to the class of calcium channel blocker, which interrupts the movement of calcium in the walls of the arteries. Nifedipine is used specifically to treat hypertension, arrhythmias, and angina. In addition, it has several other therapeutical applications such as ryanoids syndrome, cephalagra, and others.

Factors such as increase in geriatric population, healthcare expenditure, incidence of chronic diseases such as heart failure, arrhythmias, & hypertension, and healthcare awareness fuel the growth of the market. However, stringent government regulations and side-effects of the drugs such as hypotension, gastric ulcers, and congestive heart failure hinder the market growth. Ongoing R&D activities are anticipated to present new growth opportunities.

The market is segmented on the basis of product, application, and region. By product, the market is bifurcated into nifedipine controlled release tablets and nifedipine extended release tablets. Based on application, the market is categorized into primary pulmonary hypertension, heart failure, ryanoids disease, cephalagra, bronchial asthma, and premature labor. By region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

The study provides an in-depth analysis of the nifedipine market, with current trends and future estimations to elucidate investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
The report provides a quantitative analysis to help stakeholders to capitalize on prevailing market opportunities from 20172023 in terms of value.
Extensive analysis of different segments helps understand various products of the market.
Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

Nifedipine Market Key Segments:

By Product

Nifedipine Controlled Release Tablets
Nifedipine Extended Action Tablets

By Application

Primary Pulmonary Hypertension
Heart Failure
Raynauds Syndrome
Cephalagra
Bronchial Asthma
Premature Labor

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
LAMEA
- Latin America
- The Middle East
- Africa

List of players profiled in the report

GlaxoSmithKline plc
Novartis AG
Merck & Co., Inc.
Abbott Laboratories
Boehringer Ingelheim GmbH
AstraZeneca plc
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries Ltd.
Vectura Group plc
Pfizer Inc.

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 NIFEDIPINE , BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NIFEDIPINE CONTROLLED RELEASE TABLETS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NIFEDIPINE EXTENDED ACTION TABLETS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 NIFEDIPINE , BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. PRIMARY PULMONARY HYPERTENSION

5.2.1. Market size and forecast

5.3. HEART FAILURE

5.3.1. Market size and forecast

5.4. RAYNAUD’S SYNDROME

5.4.1. Market size and forecast

5.5. CEPHALAGRA

5.5.1. Market size and forecast

5.6. BRONCHIAL ASTHMA

5.6.1. Market size and forecast

5.7. PREMATURE LABOR

5.7.1. Market size and forecast

Chapter: 6 NIFEDIPINE , BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Nifedipine by Product
6.2.5. North America Nifedipine by Application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. UK market size and forecast
6.3.3.2. Germany market size and forecast
6.3.3.3. France market size and forecast
6.3.3.4. Spain market size and forecast
6.3.3.5. Italy market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Nifedipine by Product
6.3.5. Europe Nifedipine by Application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. China market size and forecast
6.4.3.2. Japan market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Nifedipine by Product
6.4.5. Asia-Pacific Nifedipine by Application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Latin America market size and forecast
6.5.3.2. The Middle East market size and forecast
6.5.3.3. Africa market size and forecast

6.5.4. LAMEA Nifedipine by Product
6.5.5. LAMEA Nifedipine by Application

Chapter: 7 COMPANY PROFILES

7.1. GLAXOSMITHKLINE PLC

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. NOVARTIS AG

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. MERCK & CO., INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. ABBOTT LABORATORIES

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. BOEHRINGER INGELHEIM GMBH

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. ASTRAZENECA PLC

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. F. HOFFMANN-LA ROCHE AG

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. TEVA PHARMACEUTICAL INDUSTRIES LTD

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. VECTURA GROUP PLC

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. PIFIZER INC.

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty